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Abstract
Background: Dengue is the most widespread mosquito-borne viral disease of public health concern. In some
patients, endothelial cell and platelet dysfunction lead to life-threatening hemorrhagic dengue fever or dengue
shock syndrome. Prognostication of disease severity is urgently required to improve patient management. The
pathogenesis of severe dengue has not been fully elucidated, and the role of host proteins associated with viral
particles has received little exploration.
Methods: The proteomes of virion-enriched fractions purified from plasma pools of patients with dengue fever or
severe dengue were compared. Virions were purified by ultracentrifugation combined with a water-insoluble
polyelectrolyte-based technique. Following in-gel hydrolysis, peptides were analyzed by nano-liquid chromatography
coupled to ion trap mass spectrometry and identified using data libraries.
Results: Both dengue fever and severe dengue viral-enriched fractions contained identifiable viral envelope proteins
and host cellular proteins. Canonical pathway analysis revealed the identified host proteins are mainly involved in the
coagulation cascade, complement pathway or acute phase response signaling pathway. Some host proteins were
over- or under-represented in plasma from patients with severe dengue compared to patients with dengue fever.
ELISAs were used to validate differential expression of a selection of identified host proteins in individual plasma
samples of patients with dengue fever compared to patients with severe dengue. Among 22 host proteins tested, two
could differentiate between dengue fever and severe dengue in two independent cohorts (olfactomedin-4: area under
the curve (AUC), 0.958; and platelet factor-4: AUC, 0.836).
Conclusion: A novel technique of virion-enrichment from plasma has allowed to identify two host proteins that have
prognostic value for classifying patients with acute dengue who are more likely to develop a severe dengue. The impact
of these host proteins on pathogenicity and disease outcome are discussed.
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Background
Infection by one of the four serotypes of the dengue
virus (DV), a member of the Flaviviridae family, can
cause a wide spectrum of clinical manifestations. Al-
though the majority of symptomatic patients develop a
febrile illness known as dengue fever (DF) with non-
specific symptoms such as headache, fever or myalgia,
around 10 % of patients develop a more severe form of
disease, severe dengue (SD), that may include plasma
leakage, severe hemorrhage and organ failure [1].
The DV genome is a positive single-stranded RNA
molecule encoding a polyprotein that is processed into
three structural proteins (the capsid protein C, the
membrane protein M, and the envelope proteins E) and
seven non-structural (NS) proteins involved in replica-
tion and pathogenicity [2]. DV enters target cells via
receptor-mediated endocytosis and traffics via the endo-
some, where the acidic environment triggers fusion of
viral and host cell membranes. Once within the target
cell, the virus manipulates the host cell membrane to
create an optimal environment for the assembly of its
replication complex and subsequent RNA amplification
[3]. Virion assembly occurs on the surface of the endo-
plasmic reticulum (ER), followed by budding of an im-
mature particle into the ER lumen. The immature virion
is then transported to the trans-Golgi network, matured
via proteolytic cleavage, and finally released by exocyt-
osis into the extracellular medium.
No specific antiviral treatment against DV currently
exists. The available therapies are symptomatic and are
administered to control the clinical manifestations. The
ability to diagnose DV infection at an early stage and
successful prognosis of the resulting complications of
dengue are urgently required to improve the manage-
ment of patients. It is possible that the identification of
proteins specifically present in plasma before the onset
of severe symptoms may ultimately lead to the discovery
of new prognostic biomarkers.
Despite an incomplete understanding of the mecha-
nisms of pathogenicity, several hypotheses have been
formulated to explain the disease process in patients in-
fected with DV. However, the lack of animal models cap-
able of reproducing the features of human disease has
hampered the identification of reliable parameters and
indicators to explain or predict the development of SD.
A number of host immune components, especially
antibodies, are associated with the pathogenicity of viral
infections. Such mechanisms include antibody-dependent
enhancement of a secondary infection or cross-reactivity
with proteins such as endothelial cell or coagulation pro-
teins [4–8]. Other immune components, including mem-
ory T-cells, innate immunity effectors and complement
factors have been shown to modulate the outcomes
[9, 10]. The DV non-structural protein 1 (NS1) may
also play a major pathogenic role, as it interacts with
host complement proteins [11, 12].
Numerous studies have investigated associations be-
tween altered levels of circulating cytokines/chemokines
and dengue severity [13, 14].
Alternatively, as there is a strong biological rationale
for investigating markers implicated in vascular patholo-
gies, many markers such as the soluble intercellular ad-
hesion molecule-1 (sICAM-1), the soluble vascular cell
adhesion molecule-1 (VCAM-1), the e-selectin or the
thrombomodulin have been identified and seemed to
correlate with disease severity [15].
Unfortunately, no clear consensus has emerged from
these studies. Predicting outcome in dengue remains
challenging, and the search for robust markers remains
crucial.
Previous studies have demonstrated patients with SD
have higher viremia than patients with DF [9, 16, 17].
Additionally, reports from Cuba and Australia have sug-
gested that circulating DV may become more virulent
through passage in successive hosts during an epidemic
[18–21].
As the virus cycle and the virus pathogenicity are
strongly linked with the host metabolism, it is assumed
that host proteins interacting with virions are a reflec-
tion of pathological status of the patient.
Therefore, in the present study, a DV-enrichment pro-
cedure combining sucrose gradient ultracentrifugation
and a polymer-based technique was developed for differ-
ential proteomic analysis of plasma pools from patients
with DF and SD by liquid chromatography coupled with
tandem mass spectrometry (LC-MS/MS). The objective
was to identify the viral proteins and the host proteins
incorporated into virions, and also the host proteins that
interact/are associated with virions. The identified markers
were validated by quantitative ELISAs using samples from
dengue patients from two different geographical regions.
The possible role of the co-identified host proteins in dis-
ease pathogenicity and the potential of these proteins as




Plasma samples were provided by the Universidad In-
dustrial de Santander, Bucaramanga, Colombia and the
Institut Pasteur, Phnom-Penh, Cambodia. Samples were
collected from dengue patients as part of retrospective
(Colombia) or prospective study (Cambodia). Both stud-
ies were reviewed and approved by the local Medical
Ethics Committees (Universidad Industrial de Santander,
Colombia; National Ethic Committee, Cambodia) and
performed in compliance with the ethical standards set out
by the Declaration of Helsinki. All patient plasma samples
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were anonymized after a physical examination and obtain-
ing informed consent. Dr Villar-Centeno (Universidad In-
dustrial de Santander, Bucaramanga, Colombia) and Dr
Philippe Buchy (Institut Pasteur, Phnom-Penh, Cambodia)
granted the authors permission to use the samples.
All samples were collected between the onset of symp-
toms and defervescence. The cases were classified as pri-
mary or secondary infections by the physician based on
hemagglutination assays performed on different DV se-
rotypes and on Japanese encephalitis virus. The serotype
and the copy number were determined by real-time
quantitative RT-PCR (qRT-PCR). DV-negative plasma
specimens from healthy donors were obtained from the
French National Blood Bank (Etablissement Français du
Sang, Lyon, France). Dengue samples were tested for the
presence of the viral NS1 protein using the Platelia™
ELISA (BioRad, Marnes-la-Coquette, France) following
the manufacturer’s instructions.
Quantification of DV RNA
RNA was extracted from the plasma using the QIAmp Viral
RNA kit (Qiagen, Hilden, Germany). Viremia was measured
using a qRTPCR kit (PrimerDesign Southampton, UK) ac-
cording to the manufacturer’s instructions. QRT-PCR was
performed in a final volume of 20 μl, containing 5 μl of ex-
tracted RNA, 10 μl of 2x Precision OneStepTM qRT-PCR
MasterMix, and 1 μl of Dengue Primer/Probe mix. Assays
were carried out using a LightCycler® 1.2 (Roche Applied
Science, Bâle, Switzerland) using the OneStep amplification
protocol recommended by the manufacturer.
Cell culture and infection
HepG2 cells (ATCC HB-8065) were cultivated at 37 °C
in 5 % CO2 in DMEM supplemented with 10 % decom-
plemented fetal calf serum, 5 × 104 IU Penicillin, 50 mg
streptomycin and 10 mM L-glutamine (Invitrogen, Paisley,
UK). The cells were infected as previously described [22]
with a serotype 3 DV (DV3, strain D78-878 Thailand) gra-
ciously provided by Dr V. Barban (Sanofi-Pasteur, Lyon,
France). Sub-confluent HepG2 cell cultures (approx. 107
cells/75 cm3 flask) were incubated with virus diluted in
serum-free culture medium at various multiplicities of in-
fection (MOIs) for 90 min, the supernatant was removed,
the cells were washed once with PBS (Invitrogen) and
10 mL of fresh complete medium was added to the cells.
After 5 days of culture, the supernatant was harvested and
clarified by centrifugation at 10,000 g for 5 min at 4 °C.
Denaturing polyacrylamide gel electrophoresis, Western
blotting and silver-staining
Following denaturation in SDS sample-buffer (Novex
Invitrogen, Paisley, UK) at 37 °C and denaturing polyacryl-
amide gel electrophoresis (PAGE) on 4–12 % polyacryl-
amide gels in SDS-MOPS buffer (NuPage Invitrogen),
samples were electro-transferred to PVDF membranes
(Millipore, Billerica, MT, USA) in 10 % CAPS-10 % metha-
nol buffer, blocked in TBS-0.1 % Tween 20–5 % skimmed
dried milk (Régilait, Macon, France), incubated with anti-E
monoclonal antibody (diluted to 1 μg/mL; BioMer-
ieux, Marcy-l’Etoile, France) followed by horseradish
peroxidase-labeled conjugate (diluted at 0.1 μg/mL;
P.A.R.I.S., Compiegne, France) for 1 h each at room
temperature (RT). After washing with TBS-0.1 % Tween
20, the proteins were revealed using the SuperSignal West
Dura Kit (Thermo Scientific, Rockford, IL, USA) and im-
aged using the VersaDoc™ Imaging System (BioRad,
Hercules, CA, USA).
Alternatively, the gels were silver-stained after electro-
phoresis using the SilverXpress Kit (Life Technologies,
Paisley, UK). Densitometry analysis was carried out
using Quantity-One software (BioRad).
Preparation of DV-enriched fractions
Five milliliters of pre-clarified plasma pools (5000 g/
10 min/4 °C; cf. Table 1) or 5 ml of pre-clarified cell cul-
ture supernatant were centrifuged for 2 h at 200,000 g
using a Beckman SW41 rotor in an Optima L90 ultra-
centrifuge (Beckman, Fullerton, CA, USA). After centri-
fugation, the pellet was dissolved in a small volume of
cold PBS (Euromedex, Souffelweyersheim, France), loaded
on a discontinuous sucrose gradient constituted of 5 ml of
60 % sucrose in PBS (w/w) and 5 ml of 20 % sucrose in
PBS (w/w), and centrifuged for 2 h at 200,000 g. The frac-
tion containing virions, located at the interface of the two
sucrose solutions, was collected, diluted ten-fold in cold
PBS, centrifuged for 2 h at 200,000 g and the pellet was re-
suspended in 200 μl of cold PBS. All centrifugation steps
were performed at 4 °C.
Ultracentrifugation was complemented by additional
purification steps using Viraffinty™ (BiotechSupportGroup,
Monmouth, USA), a water insoluble elastomeric polyelec-
trolyte developed for the capture and recovery of viruses
Table 1 Characteristics of the Colombian patients whose plasma
samples were pooled to prepare the viral-enriched fractions
DF Pool SD Pool
Number of patients 8 7
Age, mean (years) 26.8 33.7
Male/female ratio 6/2 3/4
Day of sampling, mean 3.3 2.7
Secondary infections 8 (100 %) 7 (100 %)
Viral titer (copies/mL) 4.05 106 4.13 107
NS1 positive 8 (100 %) 8 (100 %)
DV serotype 2 2 (25 %) 3 (42.8 %)
DV serotype 3 6 (75 %) 4 (57.1 %)
Data is shown as mean or number (percentage)
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[23], according to the manufacturer’s instructions. Briefly,
200 μl of MN buffer (60 mM MES pH 6.5, 150 mM NaCl)
and 100 μL of Viraffinity™ were added to the resuspended
pellet obtained after ultracentrifugation. The mixture was
incubated for 5 min at RT and centrifuged at 1000 g for
10 min. The supernatant was discarded and the pellet was
rinsed three times with MN buffer. Finally, the viral frac-
tion was separated from the polymer by heating for 5 min
at 70 °C in SDS-buffer (Novex Invitrogen). After a final
centrifugation step at 1000 g, the supernatant was har-
vested and stored at −80 °C for immunoblotting and LC-
MS/MS analysis.
In-gel digestion and LC-MS/MS analysis
The following experiments were conducted by the EDyP
laboratory (EDyP-Service, CEA Grenoble, France). The
virion-enriched preparation was loaded on a 10 % poly-
acrylamide gel and electrophoresed until all proteins en-
tered the gel. The band containing the proteins was
manually excised, washed three times in buffer contain-
ing 50 % acetonitrile and dried using 100 % acetonitrile.
The gel piece was rehydrated with 7 % H2O2 for 15 min in
the dark, washed, and incubated in a modified sequencing-
grade trypsin solution (Promega, Madison WI, USA) in
25 mM NH4HCO3 overnight at 37 °C. Peptides were ex-
tracted from the gel band via three sequential extraction
steps of 15 min each with 30 μl of 50 % acetonitrile, 30 μl
of 5 % formic acid and 30 μl of 100 % acetonitrile. The ex-
tracts were pooled, vacuum dried and resuspended in a so-
lution containing 5 % acetonitrile and 0.1 % trifluoroacetic
acid. After quantity normalization, the peptides were
analyzed by nanoliquid chromatography coupled to
tandem mass spectrometry (nanoLC–MS/MS, Ultimate
3000; Dionex, Sunnyvale, CA and LTQ-Orbitrap VelosPro;
ThermoFisher Scientific, Rockford, IL, USA). Data was
acquired using Xcalibur software (ThermoFisher Sci-
entific) and processed automatically using Mascot Dae-
mon software (version 2.2; Matrix Science, Boston,
MA, USA).
Proteins with a Mascot score higher than 40 (P <
0.05) were selected for further analysis [24]. The Mas-
cot score is a measure of the reliability of identifica-
tion: the higher the score, the better the identification.
In order to eliminate false matches and incorrect pro-
tein identification, consecutive searches against the
concatenated Swiss-Prot and Trembl_decoy databases
(versions 57.6 and 40.6 decoy database, respectively;
Homo sapiens taxonomy, 164,620 entries) were per-
formed for each sample using Mascot 2.3 software
(Matrix Science). IRMa software [25] was used to filter
the results to achieve a false positive rate lower than
1 %. In-gel digestion and LC-MS/MS analysis was per-
formed twice for each sample.
Canonical pathway analyses
Ingenuity Pathways Analysis (IPA) software (Ingenuity
Systems, Redwood City, CA, USA) was used to investi-
gate the interactions among all of the host proteins iden-
tified. Interactive pathways were generated to observe
the potential direct and indirect relationships among the
proteins that were differentially expressed in the DF and
SD samples.
Quantitative ELISA
Commercial ELISAs (USCN, Wuhan, China) targeting
potential severity markers were used to measure in du-
plicate the levels of the proteins in individual DF and SD
plasma specimen, using the protocols recommended by
the manufacturer. For each test, a standard curve was
established by serial dilution of the calibrator provided
in the kit to determine the protein concentration. The
optical density values were determined at 450 nm using
a microplate reader (Eon; BioTek, Vinooski, VT, USA).
Statistical analysis (Mann–Whitney U test, Chi-square
test) and Receiver Operating Curve analysis were per-
formed using GraphPad Prism V.4.03 software (GraphPad
Software, San Diego, CA, USA). The Mann–Whitney and
the Chi-square tests were used to examine differences in
demographic and clinical characteristics between patients
and to assess potential confounding variables. Compari-
sons of continuous variables were performed using
Mann–Whitney U test that can be applied on unknown
distributions for two small sets of observation (n < 30).
Comparisons of proportion were performed using Chi-
square test.
P < 0.05 was considered significant [26].
Results
Preparation of plasma pools for purification
Plasma obtained from patients with DF or SD were
pooled to create two samples (Table 1); all of the plasma
samples used for this step came from Colombian pa-
tients who had secondary DV serotype 2 or 3 infections,
and were collected between the onset of symptoms and
the development of severe symptoms [27]. Classification
of the infections as secondary infections and the degree
of severity were based on review of the patients’ medical
records. In these medical records, the estimation of the
severity was based on the WHO criteria of 1997 [1]. DF
and DHF grade I (Dengue Haemorrhagic Fever, minor
haemorrhages) were considered as classicdengues (not se-
vere). DHF grade III/IV (DSS, Dengue Shock Syndrome)
were considered as severe dengues. Each medical records
compiled details on platelet and blood cell counts, trans-
aminase levels, the presence/absence of warning signs
(persistent vomiting, abdominal pain…), haemorrhagic
signs (petechiae, ecchymosis, epistaxis…) or shock signs
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(cold extremities, cyanosis…) that help to the patients
classification by the physician.
The proportion of samples from male patients was
higher for the DF pool (75 %) than the SD pool (43 %).
The age of the patients (mean, 30 years) and the number
of days the samples were collected after the onset of
symptoms (mean, approximately 3 days) were similar be-
tween the two groups. No comorbidity was reported for
any patient in either group.
Each of the individual plasma samples was confirmed
as NS1-positive. The viremia of each pool was estimated
using a commercial qRT-PCR kit. All patients were posi-
tive for DV, indicating all samples were collected during
the acute phase of disease. The average number of RNA
copies per mL was 4.05 × 106 and 4.13 × 107 for the sam-
ples in the DF and the SD pools, respectively.
Isolation of the viral-enriched fraction from the plasma of
patients infected with DV
A technique based on ultracentifugation (Step 1) followed
by concentration using a commercial water-insoluble
elastomeric polyelectrolyte specially engineered for the
capture and recovery of viruses (Viraffinity™; Step 2), was
created to obtain a fraction of plasma enriched with DV
particles.
Initially, this technique was developed using the cell
culture supernatant of HepG2 cells harvested five days
after infection with DV at a MOI of 1 or 10. The sam-
ples obtained after each step of the purification process
(Step 1 and Step 1 + 2) were analyzed by Western blot-
ting using an anti-E monoclonal antibody (Fig. 1a). A
positive signal corresponding to monomeric (60 kDa)
and dimeric E protein (120 KDa) was observed in the
DV-infected samples, and became more intense after the
Viraffinity™ step (Fig. 1a, Step 1 + 2). The purity of the
Step 1 + 2 sample was assessed by electrophoresis using
denaturing PAGE and silver-staining (Fig. 1b). Bovine
serum albumin (BSA), an intense protein band of ap-
proximately 66 kDa was observed in the sample before
purification (“not purified” lanes); however, this band
was almost absent from the final purified sample (“Step
1 + 2” lane). Only a small number of bands were de-
tected in the purified sample. Densitometry indicated
that the protein complexity of the purified samples
was reduced by roughly 350-fold compared to the un-
purified samples.
Fig. 1 Characterization of the viral-enriched fraction of DV-infected HepG2 supernatant or plasma obtained from patients with dengue. a After infection
with DV at a MOI of 1 or 10, HepG2 cell culture supernatants were purified by ultracentrifugation (Step 1) followed by the use of Viraffinity™ (Step 1 + 2).
b Silver-staining assessment of the protein complexity of DV-infected HepG2 cell culture supernatant before and after purification; not diluted (lane “not
purified”), 1/10 diluted (lane “not purified 1/10”) DV-infected cell supernatant before purification or the same sample as shown in lane 1 after purification
(lane “Step 1 + 2”) were separated by denaturing polyacrylamide gel electrophoresis and silver-stained. c Electron microscopy of DV-infected HepG2
culture supernatant after ultracentrifugation. Grids were negatively stained using uranyl acetate. Bars: 50 nm, 200 nm. d Representative Western blotting
analysis of plasma pools obtained from patients with dengue after purification by ultracentrifugation and Viraffinity™ using an anti-E monoclonal
antibody. MW: molecular mass
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The presence of intact viral particles was also confirmed
by electron microscopy, which was performed by the EZUS
laboratory (Université Claude Bernard, Villeurbanne,
France). After negative staining, virions could be visual-
ized in the purified samples obtained from the super-
natant of cells infected at a MOI of 10 (Fig. 1c). The
viral membrane, including the E spikes, was visible. The
spikes observed on the virion surface are probably due
to the slightly basic pH (pH 7.5) of the PBS-buffered
solutions used during centrifugation and electron mi-
croscopy. Virions tended to aggregate in clusters of 10–20
viral particles as seen in images taken at a lower magnifi-
cation. Little background signal was observed around the
virion clusters.
Following the two-step purification process, the MOI
10 sample was also analyzed by nano-LC MS/MS. All
structural viral proteins were identified (Table 2). The E
protein peptides were the most largely represented (21
peptides; 15 single peptides). The sequence coverage for
the E protein represented 44 % of the entire protein.
The protein M, which is part of the external viral layer,
along with the E protein, was identified three times (3
single peptides) with coverage of more than 58 % of the
protein sequence. The pr peptide and capsid were also
identified (one peptide each).
In conclusion, combining ultracentrifugation with
Viraffinity polymer yielded a fraction with a considerably
reduced protein complexity that contained a large quan-
tity of enveloped virions.
This technique was then applied to the pooled plasma
samples obtained from the Colombian patients (Table 1).
After purification, the preparations were analyzed by
Western blotting using a monoclonal antibody directed
against the E viral protein (Fig. 1d, SD pool as an example).
Strong signals corresponding to monomeric (60 kDa) and
dimeric E protein (120 kDa) were observed. The E protein
was not detected in purified plasma obtained from healthy
individuals, which was tested as a mock-control.
Viral and host proteins identified by nano-LC-MS/MS in
purified plasma pools
To identify the proteins present in the purified samples
and to compare their composition, nano-LC-MS/MS
was conducted on the purified DF and SD plasma pools.
This experiment was also performed on the purified
mock-control sample to determine the host background.
The same quantity of total protein was analyzed for each
sample. These experiments were performed independ-
ently twice.
Both viral and host peptides were identified in the
purified pooled plasma samples from the patients with
DF and SD. One peptide corresponding to the viral en-
velope protein was detected twice in the SD sample; this
Table 2 DV peptides identified by LC-MS/MS analysis of the purified supernatant of HepG2 infected with DV (MOI10)
Viral protein Peptide sequence Number of peptides detected Sequence coverage (%)
Capsid C EISNMLSIINK 1 11.00
Peptide pr TASGINMCTLIAMDLGEMCDDTVTYK 1 28.57
SVALAPHVGMGLDTR 1
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peptide (GWGNGCGLLFGK) was also identified in the
purified DV-infected HepG2 supernatant (Table 2).
After removal of the mock-control background, the
remaining peptides identified in the DF and SD samples
were analyzed. In order to consolidate the results ob-
tained by nano-LC MS/MS, only proteins for which the
variance of the average number of peptides was lower
than 25 % were selected [28]; 188 host proteins met this
criterion. The SD/DF peptide ratio was calculated for
these 188 proteins (see Additional file 1). The highest
SD/DF ratio was obtained for C1s esterase (SD/DF pep-
tide ratio = 4.14) and the vitamin K-dependent protein S
(ratio = 4). The lowest ratio was obtained for beta-1
spectrin (ratio = 0.13). Six proteins were only identified
in the SD sample; consequently, the SD/DF ratio could
not be calculated for these proteins.
Canonical pathway analysis
Ingenuity Pathway Analysis (IPA) was conducted to fur-
ther elucidate the specific pathways associated with the
identified host proteins. The specific location and func-
tion of each pathway was attributed by IPA for 174 of
the 188 proteins; the most prominently represented path-
ways are illustrated in Fig. 2. The IPA diagram shows that
the highest P-values were attributed to Acute Phase Re-
sponse Signaling [−log(p-value), LP = 31], the LXR/RXR
Activation Pathway (LP = 18.4), the Complement System
(LP = 16.6), the Coagulation System (LP = 16.2) and the
Extrinsic Prothrombin Activation Pathway (LP = 12.6).
The P-values indicate the likelihood that the focus genes
in a network are found in these pathways by random
chance alone.
Although represented to a lesser degree, three pathways
related to host proteins involved in the DV cell cycle,
Clathrin-Mediated Endocytosis Signaling (LP = 10.3),
Caveolar-Mediated Endocytosis Signaling (LP = 9.2) and
the Virus Entry via Endocytic Pathway (LP = 6.05), were
also identified. Other identified pathways, including Integ-
rin (LP = 6.96) and Paxillin Signaling (LP = 6.75), corres-
pond to proteins involved in cell-matrix interactions and
cell-to-cell communication.
Figure 2 also illustrates the ratio of identified proteins
for each canonical pathway. Higher proportions of pro-
teins mapped to the Complement System (ratio = 0.34),
Coagulation System (ratio = 0.32) and Extrinsic Pro-
thrombin Activation Pathway (ratio = 0.4) than the other
pathways (ratios between 0.16 and 0.05).
IPA software was also used to investigate possible in-
teractions among all of the identified proteins and to
assess the representation of the identified proteins in
Acute Phase Response Signaling, the Complement Sys-
tem and the Coagulation System with Prothrombin Acti-
vation (see Additional file 2).
Twenty of the 50 (40 %) secreted proteins identified by
IPA as part of the Acute Phase Response Signaling pathway,
which is activated in macrophages and endothelial cells
upon infection and inflammation, were over-represented in
the pooled SD plasma sample compared to the pooled DF
plasma sample. Thirteen Complement Component proteins
were also over-represented in SD plasma, with high num-
bers of peptides identified for C1r and C1s in particular.
Complement factor C8 and complement factor B (CFB),
which are involved in the complement alternate pathway,
were only identified in the pooled SD plasma sample. The
C9 protein was enriched in the pooled DF plasma sample.
Fig. 2 Ingenuity Pathway Analysis for host proteins identified in the viral-enriched plasma fraction of patients with dengue. Pathway classification
according to canonical pathways was performed using IPA software. The x-axis represents the pathways identified. The y-axis (left) shows the −
log of the P-value calculated using Fisher’s exact test. The ratio (y-axis, right) represented by the line is calculated as follows: number of proteins
in a given pathway that meet the cutoff criteria divided by total number of proteins that make up that pathway
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The Extrinsic and Intrinsic Prothrombin Activation path-
ways are part of the Coagulation system. The majority of
the proteins involved in the Fibrinogen/Fibrin cascade (i.e.
10 proteins out of 11) were over-represented in the SD
sample compared to the DF sample.
Overall, the network analysis also provided evidence of
strong links between these three pathways. The coagula-
tion factor 2 (F2) and the C3 and C5 proteins are located
at the interface of the Coagulation System and the Com-
plement System (see Additional file 3).
Validation of the proteins in individual plasma specimens
using quantitative ELISAs
To validate the mass spectrometry data, the levels of se-
lected host proteins were assessed by quantitative ELISA
both in the virus-enriched fraction and in individual plasma
samples from DF or SD patients.
For the ELISA, proteins with a SD/DF ratio higher
than 1.3 or lower than 0.78 were selected (see Additional
file 1); other criteria, such as the number of peptides
identified in the SD sample and the availability of a com-
mercial ELISA kit were also considered. Some proteins,
such as ribosomal protein P2 (accession number P05387;
ratio = 0.6) and histone H4 (accession number P62805; ra-
tio = 0.4) were not deemed relevant enough for the study
and were consequently not tested. The proteins readily
found at high concentrations in plasma and known to
be frequent contaminants in proteomic experiments,
such as the immunoglobulin heavy chain (accession
number P01779; ratio = 2.4), were not tested. Finally, a
non-exhaustive list of 22 proteins to assay was established.
These 22 proteins were ceruloplasmin (CP), vitamin
K-dependent protein S, complement factor properdin,
antithrombin III, secretory component p85, complement
factor C1r (C1r), complement factor C1s, angiotensin,
factor 2, anti-factor VIII, serum amyloide P-component,
olfactomedin-4 (OLFM4), thrombospondin, gelsolin, plate-
let factor 4 (PF4), complement factor C1q, complement
factor B, moesin and complement factor C8. Multimerin-1,
apolipoprotein B-100 and von Willebrand factor were also
tested.
These 22 proteins were first quantified in the virus-
enriched fraction of the individual plasma samples ob-
tained from DF or SD patients of the Colombian cohort.
The ELISA signal levels for these samples were close to
background levels (purified mock-control sample); the
results were not interpretable.
To investigate the potential interaction of these proteins
with the virion, fresh plasma was incubated for various
times with purified viral particles. The change of protein
concentration before and after the incubation was assessed
by ELISA. This experiment was performed for 4 proteins
out of 22 (OLFM4, CP, C1R, PF4) and showed that no sig-
nificant signal change was observed for these proteins,
whatever the condition tested (data not shown). The virus
preparation is probably not concentrated enough to in-
duce a significant variation in host protein concentration.
Furthermore, the plasmatic concentration of the four pro-
teins is too high to be significantly affected by the interac-
tions with the virus coated in the microplates.
The ELISAs were then performed on the whole plasma
samples obtained from Colombian patients (Table 3, Co-
lombian patients). All patients had secondary infections
associated with various DV serotypes (DV1, DV2 and
DV3); all samples were collected between onset and de-
fervescence (between days 2 and 5). The male/female
Table 3 Clinical profiles of the patients whose plasma samples were analyzed by ELISA
Colombian Patients Cambodian Patients
DF (n = 15) DS (n = 15) P-value DF (n = 23) DS (n = 26) P-value
Age, average ± SD (years) 29.3 ± 0.52 28.3 ± 0.5 ns 8.6 ± 0.38 7.3 ± 0.45 ns
% male 60 % 53 % ns 56 % 35.6 % ns
Sampling (day after onset) 3.06 2.37 ns 2.6 3.2 ns
Weight, average ± SD (Kg) 60.2 ± 8.6 50.3 ± 15.6 ns 20.48 ± 0.93 18.86 ± 0.98 ns
Total cholesterol (g/L) 1.44 ± 5.4 1.29 ± 10.1 0.03 1.28 ± 0.05 0.92 ± 0.046 <0.0001
Aspartate aminotransferase (IU/L) 90.2 ± 9.75 142.7 ± 29.8 0.001 133.3 ± 23.18 302.5 ± 50.7 0.0043
Alanine aminotransferase (IU/L) 69.7 ± 11.4 90.8 ± 24.5 ns 66.9 ± 13.4 106.3 ± 21.2 ns
Viral load (copy/mL) 4.05 × 106 ± 3.5 4.1 × 107 ± 5.22 0.006 7.1 108 ± 6 2.06 108 ± 2 ns
Positive Tourniquet test 8/15 (60 %) 10/15 (66 %) ns 19/23 (82 %) 18/26 (82.6 %) ns
Hepatomegaly on ultrasound na na - 8/12 (66 %) 16/26 (61.5 %) ns
Serotype 1-2-3 1-2-3 - 1 1 -
Secondary dengue infection 15 (100 %) 15 (100 %) - 23 (100 %) 26 (100 %) -
Comorbidity 0 (0 %) 0 (0 %) - 0 (0 %) 0 (0 %) -
IU international units, ns not significant, na not applicable
Chi-square or Mann–Whitney tests were used to analyze the differences between groups
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sex ratio and age were similar between the groups of pa-
tients with DF or SD. The samples were confirmed posi-
tive for both DV by qRT-PCR and the viral NS1 protein
using a commercial ELISA (NS1 Platelia™). No comor-
bidity was recorded in any patient. Among the 22 pro-
teins tested, only CP, C1r, OLFM4 and PF4, had different
plasma concentrations between DF and SD patients. The
average concentration of C1r was higher for patients
with SD than patients with DF (P = 0.049). Moreover, the
variance between the two groups was significantly differ-
ent (P = 0.019). The protein concentration of OLFM4 was
considered higher for SD patients (P = 0.051). For CP, the
difference between the two groups was significant
(P = 0.045). The largest difference was observed for PF4
with a higher concentration for patients with DF
(P < 0.001; Fig. 3).
To further confirm the relevance of C1r, CP, OLFM4
and PF4 as potential markers to differenciate DF and
SD, plasma samples from patients with acute dengue
from Cambodia, another dengue-endemic area, were
tested. As for Colombian patients, the Cambodian pa-
tients were classified by the local physician using the
WHO classification of 1997. For the present study, pa-
tients classified DF or DHF grade I were considered as
classic dengue. Patients classified DHF grade III and IV
were considered as severe dengue. Clinical data were
collected and included details on the platelet count, trans-
aminases level, blood cells count, biochemistry (cholesterol,
triglycerides, bilirubin…), ultrasound imagery, hemorrhagic
signs (petechiae, ecchymosis, epistaxis…), the presence/or
absence of warning signs (persistent vomiting, abdominal
pain…), plasma leakage and shock signs (cold extremities,
cyanosis…).
The main characteristics of the Cambodian patients
are detailed in Table 3 (Cambodian patients). The mean
age of patients from Cambodia (about 8 years-old) was
lower than that of the Colombian patients. The male/fe-
male ratios of the DF and SD groups were similar. All
Cambodian patients were infected with serotype 1 vi-
ruses. The plasma samples were collected approximately
3 days after the onset of symptoms (=acute samples) and
also just before the discharge from the hospital (=dis-
charge samples).
In contrast to the samples obtained from the Colombian
patients, ELISAs showed that the levels of C1r and CP
were not significantly different between DF and SD pa-
tients in the Cambodian cohort (see Additional file 4);
however, concentrations of OLFM4 (P < 0.0001) and PF4
(P <0.0001) during the acute phase were significantly dif-
ferent between DF and SD plasma (Fig. 4). The OLMF4
concentration in DF patients was lower than in SD pa-
tients. In contrast, PF4 concentrations were higher in DF
patients than in SD patients and SD patients showed no
significant difference with healthy controls (n = 8).
For these two markers, at the time of discharge, con-
centrations tended to decline back to the levels observed
in controls.
Receiver operating characteristic (ROC) curves compare
sensitivity versus specificity across a range of values. ROC
curves are used to assess the discriminatory ability of each
markers. Area under the ROC curve (AUC) is another
measure of test performance. The AUC quantifies the
Fig. 3 Assessment of the protein concentrations of C1r, CP, OLFM4 and PF4 in the individual plasma samples of Colombian patients using
specific quantitative ELISAs. Each value corresponds to the mean of two independent experiments, each performed in duplicate. *: 0.01 < p < 0.05;
**: 0.005 < p < 0.01; ***: p < 0.005
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overall ability of the test to discriminate between individuals
with DF and those with SD. A perfect test (zero false posi-
tives and zero false negatives) has an AUC of 1.00.
ROC curve analysis was used to determine AUCs and
specificity/sensitivity values for OLFM4 and PF4 as
prognostic biomarkers of disease severity in Cambodian
acute patients with dengue. The ROC curves indicated
good discrimination between DF and SD as the AUC
were 0.958 for OLFM4 and 0.836 for PF4. The highest
specificity/sensitivity values obtained using this model
are summarized in Table 4. For a sensitivity of 96 %, the
specificity exceeded 62 % (PF4) or 86 %(OLMF4). When
the sensitivity reached 100 %, the specificity dropped to
56.25 % (PF4) or 82.6 % (OLFM4).
Discussion
Dengue viral infections are prevalent in tropical and
subtropical areas, and are associated with substantial
morbidity and mortality. The pathogenesis of dengue re-
mains unclear. Various proteomic approaches have been
used to characterize host-protein changes during DV in-
fection and identify prognostic biomarkers of disease se-
verity; several studies have been conducted on cells
infected in vitro [29–31]. Studies on plasma specimens
have identified a number of candidate biomarkers [32–34].
As the dynamic range for plasma proteins is large
(over 10 orders of magnitude) and the most abundant
proteins (0.1 % of the total number) constitute up to
95 % of the plasmatic protein mass, identification of bio-
markers present at low concentrations is a major chal-
lenge in proteomic studies dealing with plasma. However,
proteomic techniques are constantly being improved to
assess low abundance plasma proteins [35].
Viruses facilitate their replication and propagation by
subverting host cellular pathways and processes, and
constantly adapt to and modulate their host’s environ-
ment. Enveloped viruses are able to incorporate numer-
ous host proteins, both into virus particles as well as the
host-derived viral envelope. As the genomes of RNA vi-
ruses only encode a small number of proteins, they must
rely on host proteins during an infection. Interactions
between the virus and host may have unforeseen conse-
quences, depending on viremia level, the host’s genetic
background and other relevant factors [36]. Host pro-
teins can be incorporated into virions either randomly,
by being present at the site of budding, or specifically, as
a result of interacting with viral proteins.
The functional significance of the host proteins that
associate with viral particles remains to be thoroughly
investigated; however, it is very likely that such interactions
Fig. 4 Assessment of the protein concentrations of OLFM4 (a) and PF4 (b) in the individual plasma samples of Cambodian patients using specific
quantitative ELISAs. Patients were taken during both the acute phase (DF acute and SD acute) and at time of discharge from the hospital (DF
discharge and SD discharge). T: healthy patient samples. Each value corresponds to the mean of two independent experiments, each performed
in duplicate. **: 0.005 < p < 0.01; ***: p < 0.005
Table 4 Summary of ROC analysis of the prognostic value of OLFM4 and PF4 in the Cambodian cohort (n = 49)
AUC (95 % CI) For a sensitivity of: The highest specificity is:
OLFM4 0.958 (0.906–1) 100 % 82.6 %
96 % 86.9 %
PF4 0.836 (0.689–0.983) 100 % 56.25 %
96 % 62.5 %
AUC area under the curve, CI confidence interval
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contribute to pathogenicity if they disturb the metabolism
of the host cell [37]. For instance, the incorporation of cel-
lular proteins such as integrins or HLA class II proteins
can affect the ability of HIV-1 to infect host cells and con-
tributes to immunopathogenesis [38, 39].
Viroproteomic analyses have already been conducted
on DNA viruses [40] and RNA viruses, such as retrovi-
ruses [39, 41], paramyxoviruses [42], coronaviruses [43]
and flaviviruses [44]; these studies have proven that many
cellular proteins are incorporated into the virion or associ-
ate with the viral membrane.
Usually, prior to MS analysis, protease hydrolysis is
combined with ultracentrifugation to remove host pro-
teins that may co-purify with virions. In the present
study, as we aimed to characterize the host proteins
that interact with viral membrane proteins and parti-
cles, enzymatic hydrolysis of the proteins outside of the
virion could not be performed. Therefore, a new tech-
nique combining ultracentrifugation with water-insoluble
polyelectrolyte-based enrichment was developed to enable
proteomic characterization of a fraction of human plasma
enriched with virus particles and depleted of the host pro-
teins predominantly expressed in plasma.
Previous studies measuring viremia have demonstrated
that patients with SD have higher viremia than patients
with DF [9, 16, 17]. Higher viremia may lead to biosyn-
thesis of virions with an altered host protein compos-
ition, which may reflect an increased level of cellular
stress, or subtle changes in the assembly pathway. These
host proteins may be packaged into the virus particle
along with the viral components or incorporated into
the viral membrane. Alternatively, they can be simply
co-purified along with virions. Such proteins may poten-
tially be fingerprints of the virus assembly pathway and
may also play a role in viral pathogenicity.
Nano LC-MS/MS was used in this study to analyze
the protein composition of the virion-enriched samples
purified from the plasma pools. Some proteins had a
higher average number of peptides in the SD sample
than the DF and control samples, suggesting the pres-
ence of greater amounts of these proteins associated to
viruses purified from the plasma of patients with SD;
conversely, other proteins were mainly identified in the
samples purified from the DF plasma pool.
Interestingly, the identified host proteins belong to
three main pathways: the Complement System, the Co-
agulation System and the Acute Response Signaling
Pathway. The Complement System plays an important
role in both innate and adaptive immune responses, is
first line of defense against infectious agents, and mod-
ulates B- and T-cell responses. In Flavivirus infections,
excessively-activated complement proteins have been re-
ported to induce a deleterious, exacerbated inflammatory
response [45–47]. Recently, it has been shown that the level
of complement proteins positively correlates with the sever-
ity of dengue in Indonesian patients [48].
Coagulation is the process by which the blood changes
from a liquid to a gel. Coagulation is required to stop
blood loss and enable the subsequent repair of damaged
vessels. Hemorrhage is one of the major symptoms of
SD, and is probably caused by vasculopathy and a defi-
ciency in coagulation and fibrinolysis. The normal vascu-
lar endothelium produces inhibitors of coagulation and
fibrinolysis. Hemostasis can be impaired if the endothe-
lium is stimulated by excessive levels of cytokines or by
a pathogen, which may in turn result in thrombosis and
bleeding [49, 50].
The Acute Phase Response corresponds to the inflam-
matory response observed in response to an infection,
tissue injury or an immunological disorder [51], and is
mainly characterized by increased levels of inflammatory
factors and a change in the protein composition of plasma.
Interestingly, these changes can inhibit complement acti-
vation [52].
Interconnections between the coagulation process and
complement cascade have been reported by many au-
thors [53, 54]. Deregulation of one or both systems can
result in the clinical manifestations of diseases with inflam-
matory complications. In a previous study, differentially-
expressed genes associated with the immune response
were identified by microarray analysis of peripheral blood
mononuclear cells isolated from Colombian children with
dengue fever or dengue hemorrhagic fever. These results
indicated that the complement and numerous cytokines
are deregulated in patients with dengue-hemorrhagic fever.
Such changes may enhance disease severity by disturbing
coagulation and inducing endothelial cell damage [55]. In
another recent study, sera from Indian patients with DF
were compared with that of healthy controls using 2D-
DIGE associated with MALDI TOF/TOF MS. The authors
reported that DV infection led to altered expression of
multiple serum proteins involved in complement cascades,
blood coagulation and acute phase response signaling, pro-
viding further clues regarding the pathogenesis and host
immune response to DV infection [56].
The Complement System, Coagulation System and
Acute Response Signaling Pathway are strongly intercon-
nected and share proteins whose expression is modu-
lated during an infection. They are all related to the
inflammatory process and the innate immune response,
and act upstream of activation of the adaptive immune
response. Expression deregulation of these proteins
could induce deleterious effects in endothelial cells [57].
In our hands, none of the seven complement proteins
tested by ELISA showed a difference in concentration
levels between SD and DF acute samples, minimizing
the potential role of these proteins in dengue pathogen-
esis, at least in the early phase of the disease.
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Several authors have reported proteomic analysis of sam-
ples from patients with dengue using different approaches
[29, 30, 32]. To our knowledge, this study is the first assess-
ment of the proteins that are differentially present in a
virus-enriched fraction purified from plasma specimens ob-
tained from patients during the acute stage of DV infection.
We were unable to confirm that proteins identified by
LC-MS/MS were directly associated with the viral parti-
cles. Neither ELISAs conducted on virions purified from
plasma, nor electron microscopy using specific gold-
labeled antibodies succeed to yield reliable results. Con-
sequently, we cannot discard the possibility that the host
proteins identified in this study may be contaminants
that co-purify reproducibly with viral particles.
ELISAs carried out on individual plasma specimens
from the Colombian cohort indicated trends towards
higher levels of CP, C1r and OLFM4 in patients with SD
compared to patients with DF.
CP, an acute phase protein, is a ferroxidase involved in
iron metabolism. Elevated levels of CP are generally ob-
served during inflammation. C1r is a complement pro-
tein that interacts with C1s at the beginning of the
complement cascade. OLFM4 is an anti-apoptotic factor
that promotes tumor growth and facilitates cell adhe-
sion, probably via interacting with cell surface lectins
and cadherin [58]. The associations between these pro-
teins and disease severity in dengue remain to be explored.
Interestingly, a recent paper mentioned the interest of
OLFM4 as a marker of disease severity in Respiratory Syn-
cytial Virus infection in children [59].
ELISAs also showed that the concentration of PF4 was
higher in the plasma samples of Colombian patients with
DF than patients with SD. PF4 is a small cytokine re-
leased by platelets that promotes blood coagulation by
moderating the effects of heparin-like molecules. PF4
also plays a role in wound repair and inflammation. Al-
terations in platelet function have been associated with
plasma leakage, which is one of the major features of se-
vere disease in patients with dengue [60]. Recently, it
has been demonstrated that DV replicates and produces
infectious virus in platelets [61]. In 1989, Srichaikul T.
et al. demonstrated that the level of PF4 increases during
acute phase in both shock or non-shock DHF children.
It is difficult to compare these results with the results
presented here because there is no strict correspondence
between the patient classification used by Srichaikul T.
et al. and the classification of 1997 used in the present
work [62]. Interestingly, among the six proteins involved
in coagulation and having a SD/DF peptide ratio higher
than 1.3 or lower than 0.78 (see Additional file 1), PF4 is
the only one that was confirmed by ELISA. PF4 is sig-
nificantly less concentrated in SD acute patient plasma.
The trends observed for OLFM4 and PF4 by ELISAs
for the Colombian patients were also confirmed in the
Cambodian patients. By testing different time points
during the course of the disease, we showed that these
markers evolved through time and tended, during the
process of healing, to get close to the protein concentra-
tion found in healthy patients. PF4 was overabundant in
DF acute patients, but remained surprisingly low in SD
patients, with levels remaining similar to control individ-
uals. It has previously been proposed that PF4 interacts
with the vasculature and is involved in thrombus forma-
tion at sites of vascular injury [63]. Murine studies sug-
gest that PF4 may have an overall salutary effect in
sepsis [64]. Therefore, a basal level of PF4 expression
during the acute phase of DV infection could be an in-
teresting marker of a future severe dengue.
The severity of dengue is modulated by multiple risk
factors such as the age, genetic background and nutri-
tional status of the host, as well as the genotype and
serotype of the virus. These factors could explain the dif-
ferences in the concentrations of specific markers ob-
served between the plasma samples from the Colombian
and Cambodian patients. For example, SD in South-East
Asia is mainly observed in children, whereas adults are
predominantly affected in South America [65]. As a
consequence, results should be extrapolated with cau-
tion to different geographic areas or different demo-
graphic groups.
Conclusion
In conclusion, we describe the development of a novel
technique of DV-enrichment from complex biological
fluids based on centrifugation combined with a water-
insoluble polyelectrolyte-based technique, for subse-
quent proteomic analyses. We found no evidence that
the identified host proteins are specifically associated
with virions. However, this purification technique en-
ables the analysis of a plasma fraction enriched in virions
and from which the most abundant plasma proteins
were removed. The host proteins characterized in this
study may potentially reflect how DV infection disturbs
the function of the cellular proteome. In this regard, fur-
ther studies are required to assess the prognostic value
of host proteins associated with inflammation, comple-
ment cascade and coagulation for disease severity by
analysis of additional biological samples from patients
infected with DV.
Analysis of a selection of the identified proteins using
ELISAs identified two host proteins, OLFM4 and PF4,
which had significant prognostic value for classifying pa-
tients with dengue who were likely to develop SD. Fur-
ther prospective studies are warranted to confirm and
validate the prognostic value of OLFM4 and PF4 as po-
tential biomarkers of disease severity in larger cohorts of
patients from a variety of dengue-endemic areas around
the globe.
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Abbreviations
AUC: Area Under the Curve; C1R: Complement factor 1R; CI: Confidence
Interval; CP: ceruloplasmin; DF: Dengue Fever; DIGE: Difference Gel
Electrophoresis; DV: Dengue Virus; ELISA: Enzyme Linked ImmunoSorbent
Assay; ER: Endoplasmic Reticulum; IU: International Unit; LC-MS/MS: Liquid
Chromatography coupled to Mass Spectrometry chain; MES: 2-(N-
Morpholino)EthaneSulfonic acid; MOI: Multiplicity of Infection; NA: not
applicable; NS: Non-Structural; OLFM4: olfactomedin-4; PAGE: PolyAcrylamide
Gel Electrophoresis; PBS: Phosphate Buffer Saline; PF4: Platelet Factor-4; qRT-
PCR: quantitative Reverse-Transcriptase Polymerase Chain Reaction;
RNA: RiboNucleic Acids; ROC: Receiving Operating Curve; SD: Severe Dengue;
SDS: Sodium Dodecyl Sulfate.
Competing interests
AP and FB are employed by BioMerieux SA.
Authors’ contributions
RF, MF, FR and FB carried out all the experiments and performed the
statistical analysis. RF and FB drafted the manuscript. AP, FR and GB
participated in the design of the study. RF, FB, GB participated to draft the
manuscript. DV and PB collected Cambodian samples and managed the
patient data and ethics. All authors read and approved the final manuscript.
Acknowledgements
We would like to thank Dr. Y. Coute and Dr. A. Kraut (EDyP Service, CEA
Grenoble, France) for their valuable support in mass spectrometry
experiments and analysis, and Dr. A. Rivoire (Centre de Microscopie
Electronique EZUS, Villeurbanne, France) for her technical guidance in
electron microscopy studies. We would also like to thank Drs. L. Villar-Centeno
(Universidad Industrial de Santander, Bucaramanga, Colombia) for
providing Colombian samples, Hader Haidous (Clinical affairs, BioMerieux,
France) for help in the management of patient folders, Yasemin Ataman-Onal
and Florence Frager for critical reading of the manuscript. This work was funded
by BioMerieux SA.
Author details
1MD3 Department, BioMerieux SA, 69280 Marcy l’Etoile, France. 2UMR 3569
de Virologie Structurale, Institut Pasteur, 75015 Paris, France. 3BioASTER,
60007 Lyon, France. 4Unité de Virologie, Institut Pasteur Phnom-Penh,
Phnom-Penh, Cambodia. 5Emerging Pathogens Laboratory Fondation
Merieux, 69007 Lyon, France. 6MD3 & NAD Departments, BioMerieux SA,
69280 Marcy l’Etoile, France.
Received: 28 July 2015 Accepted: 6 November 2015
References
1. World Health Organization. Dengue: Guidelines for Diagnosis, Treatment,
Prevention and Control: New Edition. Geneva: World Health Organization;
2009.
2. Clyde K, Kyle JL, Harris E. Recent advances in deciphering viral and host
determinants of dengue virus replication and pathogenesis. J Virol.
2006;80:11418–31.
3. Miller S, Krijnse-Locker J. Modification of intracellular membrane structures
for virus replication. Nat Rev Microbiol. 2008;6:363–74.
4. Falconar AK. The dengue virus nonstructural-1 protein (NS1) generates
antibodies to common epitopes on human blood clotting, integrin/adhesin
proteins and binds to human endothelial cells: potential implications in
haemorrhagic fever pathogenesis. Arch Virol. 1997;142:897–916.
5. Halstead SB. Dengue. Lancet. 2007;370:1644–52.
6. Lin YS, Yeh TM, Lin CF, Wan SW, Chuang YC, Hsu TK, et al. Molecular
mimicry between virus and host and its implications for dengue disease
pathogenesis. Exp Biol Med. 2011;236:515–23.
7. Malasit P. Complement and dengue haemorrhagic fever/shock syndrome.
Southeast Asian J Trop Med Public Health. 1987;18:316–20.
8. Lin CF, Chiu SC, Hsiao YL, Wan SW, Lei HY, Shiau AL, et al. Expression of
cytokine, chemokine, and adhesion molecules during endothelial cell
activation induced by antibodies against dengue virus nonstructural protein
1. J Immunol. 2005;174:395–403.
9. Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S,
Auethavornanan K, et al. Vascular leakage in severe dengue virus infections:
a potential role for the nonstructural viral protein NS1 and complement.
J Infect Dis. 2006;193:1078–88.
10. de Kruif MD, Setiati TE, Mairuhu AT, Koraka P, Aberson HA, Spek CA, et al.
Differential gene expression changes in children with severe dengue virus
infections. PLoS Negl Trop Dis. 2008;2, e215.
11. Avirutnan P, Fuchs A, Hauhart RE, Somnuke P, Youn S, Diamond MS, et al.
Antagonism of the complement component C4 by flavivirus nonstructural
protein NS1. J Exp Med. 2010;207:793–806.
12. Avirutnan P, Hauhart RE, Somnuke P, Blom AM, Diamond MS, Atkinson JP.
Binding of flavivirus nonstructural protein NS1 to C4b binding protein
modulates complement activation. J Immunol. 2011;187:424–33.
13. Rathakrishnan A, Wang SM, Hu Y, Khan AM, Ponnampalavanar S, Lum LC,
et al. Cytokine expression profile of dengue patients at different phases of
illness. PLoS ONE. 2012;7:e52215.
14. Butthep P, Chunhakan S, Yoksan S, Tangnararatchakit K, Chuansumrit A.
Alteration of cytokines and chemokines during febrile episodes associated
with endothelial cell damage and plasma leakage in dengue hemorrhagic
fever. Pediatr Infect Dis J. 2012;31:e232–8.
15. Yacoub S, Wills B. Predicting outcome from dengue. BMC Med. 2014;12:147.
16. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, et al.
Relationship of preexisting dengue virus (DV) neutralizing antibody levels to
viremia and severity of disease in a prospective cohort study of DV
infection in Thailand. J Infect Dis. 2004;189:990–1000.
17. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn
S, et al. Dengue viremia titer, antibody response pattern, and virus serotype
correlate with disease severity. J Infect Dis. 2000;181:2–9.
18. Guzman MG, Kouri G, Halstead SB. Do escape mutants explain rapid
increases in dengue case-fatality rates within epidemics? Lancet.
2000;355:1902–3.
19. Kouri GP, Guzman MG, Bravo JR. Why dengue haemorrhagic fever in Cuba?
2. An integral analysis. Trans R Soc Trop Med Hyg. 1987;81:821–3.
20. Kouri GP, Guzman MG, Bravo JR, Triana C. Dengue haemorrhagic fever/
dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull
World Health Organ. 1989;67:375–80.
Fragnoud et al. BMC Infectious Diseases  (2015) 15:518 Page 13 of 14
21. Streatfield R, Bielby G, Sinclair D. A primary dengue 2 epidemic with
spontaneous haemorrhagic manifestations. Lancet. 1993;342:560–1.
22. Steidel M, Fragnoud R, Guillotte M, Roesch C, Michel S, Meunier T, et al.
Nonstructural protein NS1 immunodominant epitope detected specifically
in dengue virus infected material by a SELDI-TOF/MS based assay. J Med
Virol. 2012;84:490–9.
23. Shinohara M, Uchida K, Shimada S, Tomioka K, Suzuki N, Minegishi T, et al.
Application of a simple method using minute particles of amorphous
calcium phosphate for recovery of norovirus from cabbage, lettuce, and
ham. J Virol Methods. 2013;187:153–8.
24. Peng J, Elias JE, Thoreen CC, Licklider LJ, Gygi SP. Evaluation of
multidimensional chromatography coupled with tandem mass
spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast
proteome. J Proteome Res. 2003;2:43–50.
25. Dupierris V, Masselon C, Court M, Kieffer-Jaquinod S, Bruley C. A toolbox for
validation of mass spectrometry peptides identification and generation of
database: IRMa. Bioinformatics. 2009;25:1980–1.
26. Laplanche A, Comnougue C, Flamant R. Methodes statistiques appliquees a
la recherche clinique. Paris: Medecine Sciences Flammarion; 1993.
27. Villar-Centeno LA, Diaz-Quijano FA, Martinez-Vega RA. Biochemical
alterations as markers of dengue hemorrhagic fever. Am J Trop Med Hyg.
2008;78:370–4.
28. Stalder D, Haeberli A, Heller M. Evaluation of reproducibility of protein
identification results after multidimensional human serum protein
separation. Proteomics. 2008;8:414–24.
29. Pattanakitsakul SN, Poungsawai J, Kanlaya R, Sinchaikul S, Chen ST,
Thongboonkerd V. Association of Alix with late endosomal
lysobisphosphatidic acid is important for dengue virus infection in human
endothelial cells. J Proteome Res. 2010;9:4640–8.
30. Pattanakitsakul SN, Rungrojcharoenkit K, Kanlaya R, Sinchaikul S, Noisakran S,
Chen ST, et al. Proteomic analysis of host responses in HepG2 cells during
dengue virus infection. J Proteome Res. 2007;6:4592–600.
31. Chiu HC, Hannemann H, Heesom KJ, Matthews DA, Davidson AD. High-
throughput quantitative proteomic analysis of dengue virus type 2 infected
A549 cells. PLoS ONE. 2014;9, e93305.
32. Brasier AR, Garcia J, Wiktorowicz JE, Spratt HM, Comach G, Ju H, et al.
Discovery proteomics and nonparametric modeling pipeline in the
development of a candidate biomarker panel for dengue hemorrhagic
fever. Clin Transl Sci. 2012;5:8–20.
33. Fragnoud R, Yugueros-Marcos J, Pachot A, Bedin F. Isotope Coded Protein
Labeling analysis of plasma specimens from acute severe dengue fever
patients. Proc Natl Acad Sci U S A. 2012;10:60.
34. Kumar Y, Liang C, Bo Z, Rajapakse JC, Ooi EE, Tannenbaum SR. Serum
proteome and cytokine analysis in a longitudinal cohort of adults with
primary dengue infection reveals predictive markers of DHF. PLoS Negl Trop
Dis. 2012;6, e1887.
35. Mottaz-Brewer HM, Norbeck AD, Adkins JN, Manes NP, Ansong C, Shi L,
et al. Optimization of proteomic sample preparation procedures for
comprehensive protein characterization of pathogenic systems. J Biomol
Tech. 2008;19:285–95.
36. Noisakran S, Perng GC. Alternate hypothesis on the pathogenesis of dengue
hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in dengue virus
infection. Exp Biol Med. 2008;233:401–8.
37. Ott DE. Potential roles of cellular proteins in HIV-1. Rev Med Virol.
2002;12:359–74.
38. Bounou S, Giguere JF, Cantin R, Gilbert C, Imbeault M, Martin G, et al. The
importance of virus-associated host ICAM-1 in human immunodeficiency
virus type 1 dissemination depends on the cellular context. FASEB J.
2004;18:1294–6.
39. Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess Jr JW, et al.
Proteomic and biochemical analysis of purified human immunodeficiency
virus type 1 produced from infected monocyte-derived macrophages.
J Virol. 2006;80:9039–52.
40. Lind SB, Artemenko KA, Pettersson U. Proteome analysis of adenovirus using
mass spectrometry. Methods Mol Biol. 2014;1089:25–44.
41. Segura MM, Garnier A, Di Falco MR, Whissell G, Meneses-Acosta A, Arcand
N, et al. Identification of host proteins associated with retroviral vector
particles by proteomic analysis of highly purified vector preparations. J Virol.
2008;82:1107–17.
42. Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. Cellular proteins in
influenza virus particles. PLoS Pathog. 2008;4, e1000085.
43. Kong Q, Xue C, Ren X, Zhang C, Li L, Shu D, et al. Proteomic analysis of
purified coronavirus infectious bronchitis virus particles. Proc Natl Acad Sci
U S A. 2010;8:29.
44. Okamoto K, Endo Y, Inoue S, Nabeshima T, Nga PT, Guillermo PH, et al.
Development of a rapid and comprehensive proteomics-based arboviruses
detection system. J Virol Methods. 2010;167:31–6.
45. Bokisch VA, Muller-Eberhard HJ, Dixon FJ. The role of complement in
hemorrhagic shock syndrome (dengue). Trans Assoc Am Physicians.
1973;86:102–10.
46. Bokisch VA, Top Jr FH, Russell PK, Dixon FJ, Muller-Eberhard HJ. The
potential pathogenic role of complement in dengue hemorrhagic shock
syndrome. N Engl J Med. 1973;289:996–1000.
47. Morrison TE, Heise MT. The host complement system and arbovirus
pathogenesis. Curr Drug Targets. 2008;9:165–72.
48. Yamanaka A, Hendrianto E, Mulyatno KC, Susilowati H, Ginting AP, Sary DD,
et al. Correlation between complement component levels and disease
severity in dengue patients in Indonesia. Jpn J Infect Dis. 2013;66:366–74.
49. Bhamarapravati N. Hemostatic defects in dengue hemorrhagic fever. Rev
Infect Dis. 1989;11 Suppl 4:S826–9.
50. Mairuhu AT, Mac Gillavry MR, Setiati TE, Soemantri A, Ten CH, Brandjes DP,
et al. Is clinical outcome of dengue-virus infections influenced by
coagulation and fibrinolysis? A critical review of the evidence. Lancet Infect
Dis. 2003;3:33–41.
51. Moshage H. Cytokines and the hepatic acute phase response. J Pathol.
1997;181:257–66.
52. Huang Y, Krein PM, Muruve DA, Winston BW. Complement factor B gene
regulation: synergistic effects of TNF-alpha and IFN-gamma in macrophages.
J Immunol. 2002;169:2627–35.
53. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement
and coagulation: strangers or partners in crime? Trends Immunol.
2007;28:184–92.
54. Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between
coagulation and complement–their role in inflammation. Semin
Immunopathol. 2012;34:151–65.
55. Houghton-Trivino N, Martin K, Giaya K, Rodriguez JA, Bosch I, Castellanos JE.
Comparison of the transcriptional profiles of patients with dengue fever
and dengue hemorrhagic fever reveals differences in the immune response
and clues in immunopathogenesis. Biomedica. 2010;30:587–97.
56. Ray S, Srivastava R, Tripathi K, Vaibhav V, Patankar S, Srivastava S. Serum
proteome changes in dengue virus-infected patients from a dengue-
endemic area of India: towards new molecular targets? OMICS.
2012;16:527–36.
57. Khadka S, Vangeloff AD, Zhang C, Siddavatam P, Heaton NS, Wang L, et al.
A physical interaction network of dengue virus and human proteins. Mol
Cell Proteomics. 2011;10:M111.
58. Liu W, Lee HW, Liu Y, Wang R, Rodgers GP. Olfactomedin 4 is a novel target
gene of retinoic acids and 5-aza-2′-deoxycytidine involved in human
myeloid leukemia cell growth, differentiation, and apoptosis. Blood.
2010;116:4938–47.
59. Brand HK, Ahout IM, de Ridder D, van Diepen A, Li Y, Zaalberg M, et al.
Olfactomedin 4 Serves as a Marker for Disease Severity in Pediatric
Respiratory Syncytial Virus (RSV) Infection. PloS ONE. 2015;10:e0131927.
60. Michels M, Alisjahbana B, De Groot PG, Indrati AR, Fijnheer R, Puspita M,
et al. Platelet function alterations in dengue are associated with plasma
leakage. Thromb Haemost. 2014;112:352–62.
61. Simon AY, Sutherland MR, Pryzdial EL. Dengue virus binding and replication
by platelets. Blood. 2015;126:378–85.
62. Srichaikul T, Nimmannitya S, Sripaisarn T, Kamolsilpa M, Pulgate C. Platelet
function during the acute phase of dengue hemorrhagic fever. Southeast
Asian J Trop Med Public Health. 1989;20:19–25.
63. Sachais BS, Higazi AA, Cines DB, Poncz M, Kowalska MA. Interactions of
platelet factor 4 with the vessel wall. Semin Thromb Hemost. 2004;30:351–8.
64. Kowalska MA, Rauova L, Poncz M. Role of the platelet chemokine platelet
factor 4 (PF4) in hemostasis and thrombosis. Thromb Res. 2010;125:292–6.
65. Back AT, Lundkvist A. Dengue viruses - an overview. Infect Ecol Epidemiol.
2013;3.
Fragnoud et al. BMC Infectious Diseases  (2015) 15:518 Page 14 of 14
